Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02484092 · ClinicalTrials.gov registry record · Phase 2

A Gene Therapy Study for Hemophilia B

A Phase 2 study, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
15
Enrollment target

NCT02484092 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02484092, a Phase 2 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
15 participants
Enrollment target

Study Summary

A Phase 1/2, Open-Label, Non-Randomized, Dose-Escalation Study of SPK-9001 in Subjects with Hemophilia B.

Interventions

  • BIOLOGICAL SPK-9001

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2015-11-18
Est. Completion 2019-04-08
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT02484092

The ClinicalTrials.gov registry entry for NCT02484092 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which SPK-9001 is the first listed.

NCT02484092 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02484092 about?

NCT02484092 is a clinical study titled "A Gene Therapy Study for Hemophilia B". A Phase 1/2, Open-Label, Non-Randomized, Dose-Escalation Study of SPK-9001 in Subjects with Hemophilia B.

What is the current status of trial NCT02484092?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2015-11-18. Estimated completion is 2019-04-08.

What interventions are being tested in trial NCT02484092?

The interventions under investigation include: SPK-9001 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02484092?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.